251 related articles for article (PubMed ID: 8128360)
1. Stimulation of vasoactive intestinal peptide and neurotensin secretion by pentagastrin in a patient with VIPoma syndrome.
Brunt LM; Mazoujian G; O'Dorisio TM; Wells SA
Surgery; 1994 Mar; 115(3):362-9. PubMed ID: 8128360
[TBL] [Abstract][Full Text] [Related]
2. In vitro release of vasoactive intestinal polypeptide and pancreatic polypeptide from human VIPoma cells and its inhibition by somatostatin analogue (SMS 201-995).
Yasunami Y; Funakoshi A; Ryu S; Shinozaki H; Jimi A; Miyazaki K; Ikeda S
Surgery; 1994 Jun; 115(6):713-7. PubMed ID: 8197564
[TBL] [Abstract][Full Text] [Related]
3. A multihormonal tumor of the pancreas producing neurotensin associated with the WDHA syndrome. Histology, histochemistry and origin.
Bani-Sacchi T; Bartolini G; Biliotti G
Histol Histopathol; 1986 Apr; 1(2):187-95. PubMed ID: 2856535
[TBL] [Abstract][Full Text] [Related]
4. Preoperative localization of a vasoactive intestinal peptide-secreting tumor by transhepatic portal venous sampling.
Parkman HP; Malet PF; Ogorek CP; Burke DR; Deveney CW
Am J Gastroenterol; 1988 May; 83(5):559-63. PubMed ID: 2834945
[TBL] [Abstract][Full Text] [Related]
5. Vasoactive intestinal peptide (VIP) secreting tumour of the pancreas.
Sandström R; Alhava EM; Poikolainen E; Puittinen J; Soimakallio S
Ann Chir Gynaecol; 1981; 70(3):124-7. PubMed ID: 6275768
[TBL] [Abstract][Full Text] [Related]
6. Release of regulatory gut peptides somatostatin, neurotensin and vasoactive intestinal peptide by acid and hyperosmolal solutions in the intestine in conscious rats.
Rudholm T; Wallin B; Theodorsson E; Näslund E; Hellström PM
Regul Pept; 2009 Jan; 152(1-3):8-12. PubMed ID: 18992283
[TBL] [Abstract][Full Text] [Related]
7. Characterization of a pancreatic tumor containing vasoactive intestinal peptide, neurotensin, and pancreatic polypeptide.
Shulkes A; Boden R; Cook I; Gallagher N; Furness JB
J Clin Endocrinol Metab; 1984 Jan; 58(1):41-8. PubMed ID: 6315763
[TBL] [Abstract][Full Text] [Related]
8. Pancreatic vasoactive intestinal polypeptide-secreting tumor: report of a case.
Sheu HW; Chou SY; Yang KC; Kao CR; Yang TL; Shih CC
Taiwan Yi Xue Hui Za Zhi; 1989 Sep; 88(9):931-5. PubMed ID: 2559939
[TBL] [Abstract][Full Text] [Related]
9. [Pancreatic vipoma with bizarre characteristics].
Bermejo F; Moreno L; Moreira V; Gisbert JP; González Palacios F; García López JL
Gastroenterol Hepatol; 1999 Mar; 22(3):132-5. PubMed ID: 10228323
[TBL] [Abstract][Full Text] [Related]
10. VIPomas: an update in diagnosis and management in a series of 11 patients.
Nikou GC; Toubanakis C; Nikolaou P; Giannatou E; Safioleas M; Mallas E; Polyzos A
Hepatogastroenterology; 2005; 52(64):1259-65. PubMed ID: 16001675
[TBL] [Abstract][Full Text] [Related]
11. Chronic pancreatitis and diabetes mellitus: plasma and gastroduodenal mucosal profiles of regulatory peptides (gastrin, motilin, secretin, cholecystokinin, gastric inhibitory polypeptide, somatostatin, VIP, substance P, pancreatic polypeptide, glucagon, enteroglucagon, neurotensin).
Domschke S; Bloom SR; Adrian TE; Lux G; Domschke W
Hepatogastroenterology; 1988 Oct; 35(5):229-37. PubMed ID: 2465985
[TBL] [Abstract][Full Text] [Related]
12. Symptomatic secondary hormone syndromes in patients with established malignant pancreatic endocrine tumors.
Wynick D; Williams SJ; Bloom SR
N Engl J Med; 1988 Sep; 319(10):605-7. PubMed ID: 2842676
[TBL] [Abstract][Full Text] [Related]
13. Vasoactive intestinal peptide (VIP) stimulates in vitro growth of VIP-1 receptor-bearing human pancreatic adenocarcinoma-derived cells.
Jiang S; Kopras E; McMichael M; Bell RH; Ulrich CD
Cancer Res; 1997 Apr; 57(8):1475-80. PubMed ID: 9108448
[TBL] [Abstract][Full Text] [Related]
14. Release of somatostatin, neurotensin and vasoactive intestinal peptide upon inhibition of gastric acid secretion by duodenal acid and hyperosmolal solutions in the conscious rat.
Wallin C; Grupcev G; Emås S; Theodorsson E; Hellström PM
Acta Physiol Scand; 1995 Jun; 154(2):193-203. PubMed ID: 7572215
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis and treatment of pancreatic vasoactive intestinal peptide endocrine tumors.
Song S; Shi R; Li B; Liu Y
Pancreas; 2009 Oct; 38(7):811-4. PubMed ID: 19657309
[TBL] [Abstract][Full Text] [Related]
16. [Vasoactive intestinal peptide-producing tumor (ViPoma)].
Doi R; Tsukada T
Nihon Rinsho; 2006 Sep; Suppl 3():358-62. PubMed ID: 17022564
[No Abstract] [Full Text] [Related]
17. Use of calcium provocative test in the diagnosis of gastroenteropancreatic endocrine tumors.
Vezzadini C; Poggioli R; Casoni I; Vezzadini P
Panminerva Med; 1996 Dec; 38(4):255-8. PubMed ID: 9063035
[TBL] [Abstract][Full Text] [Related]
18. [Long-term therapy of a metastasizing pancreatic vipoma using the somatostatin derivative octreotide].
Flückiger A; Schlup P
Schweiz Med Wochenschr; 1992 Aug; 122(33):1221-3. PubMed ID: 1326786
[TBL] [Abstract][Full Text] [Related]
19. Peptide histidine-methionine immunoreactivity in plasma and tissue from patients with vasoactive intestinal peptide-secreting tumors and watery diarrhea syndrome.
Yiangou Y; Williams SJ; Bishop AE; Polak JM; Bloom SR
J Clin Endocrinol Metab; 1987 Jan; 64(1):131-9. PubMed ID: 3023426
[TBL] [Abstract][Full Text] [Related]
20. Effects of vasoactive intestinal peptide on resting and pentagastrin-stimulated lower esophageal sphincter pressure.
Domschke W; Lux G; Domschke S; Strunz U; Bloom SR; Wünsch E
Gastroenterology; 1978 Jul; 75(1):9-12. PubMed ID: 401103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
